130 related articles for article (PubMed ID: 7813120)
1. Effect of increased myocardial cyclic GMP induced by cyclic GMP-phosphodiesterase inhibition on oxygen consumption and supply of rabbit hearts.
Weiss HR; Rodriguez E; Tse J; Scholz PM
Clin Exp Pharmacol Physiol; 1994 Aug; 21(8):607-14. PubMed ID: 7813120
[TBL] [Abstract][Full Text] [Related]
2. Altered relationship between cyclic GMP and myocardial O2 consumption in renal hypertension-induced cardiac hypertrophy.
Rabindranauth P; Scholz PM; Tse J; Naim KL; Weiss HR
Res Exp Med (Berl); 1998 Jul; 198(1):11-21. PubMed ID: 9706666
[TBL] [Abstract][Full Text] [Related]
3. Cyclic GMP-phosphodiesterase inhibition does not alter cerebral oxygen consumption.
Wei HM; Shah AJ; Tse J; Chi OZ; Weiss HR
Neurochem Res; 1996 Jan; 21(1):41-6. PubMed ID: 8833222
[TBL] [Abstract][Full Text] [Related]
4. Lack of effect of zaprinast on methacholine-induced contraction and inositol 1,4,5-trisphosphate accumulation in bovine tracheal smooth muscle.
Chilvers ER; Giembycz MA; Challiss RA; Barnes BJ; Nahorski SR
Br J Pharmacol; 1991 May; 103(1):1119-25. PubMed ID: 1652339
[TBL] [Abstract][Full Text] [Related]
5. Effects of zaprinast and rolipram on platelet aggregation and arrhythmias following myocardial ischaemia and reperfusion in anaesthetized rabbits.
Holbrook M; Coker SJ
Br J Pharmacol; 1991 Aug; 103(4):1973-9. PubMed ID: 1655149
[TBL] [Abstract][Full Text] [Related]
6. Functional interaction of a beta-adrenergic agonist and cyclic GMP phosphodiesterase inhibitor in control and hypertrophic cardiomyocytes.
Zhang S; Rodriguez R; Scholz PM; Weiss HR
Pharmacology; 2006; 76(2):53-60. PubMed ID: 16276122
[TBL] [Abstract][Full Text] [Related]
7. Reduced myocardial cyclic GMP increases myocardial O2 consumption in control but not renal hypertension-induced cardiac hypertrophy.
Sadoff JD; Scholz PM; Tse J; Weiss HR
Cardiovasc Res; 1997 Dec; 36(3):453-9. PubMed ID: 9534866
[TBL] [Abstract][Full Text] [Related]
8. Negative metabolic effects of cyclic GMP are altered in renal hypertension induced cardiac hypertrophy.
Rabindranauth P; Naim KL; Scholz PM; Tse J; Sadoff JD; Weiss HR
Basic Res Cardiol; 1997 Feb; 92(1):8-16. PubMed ID: 9062647
[TBL] [Abstract][Full Text] [Related]
9. Zaprinast increases cyclic GMP levels in plasma and in aortic tissue of rats.
Dundore RL; Clas DM; Wheeler LT; Habeeb PG; Bode DC; Buchholz RA; Silver PJ; Pagani ED
Eur J Pharmacol; 1993 Nov; 249(3):293-7. PubMed ID: 8287916
[TBL] [Abstract][Full Text] [Related]
10. N omega-nitro-L-arginine attenuates the accumulation of aortic cyclic GMP and the hypotension produced by zaprinast.
Dundore RL; Pratt PF; O'Connor B; Buchholz RA; Pagani ED
Eur J Pharmacol; 1991 Jul; 200(1):83-7. PubMed ID: 1663042
[TBL] [Abstract][Full Text] [Related]
11. Effects of rolipram, pimobendan and zaprinast on ischaemia-induced dysrhythmias and on ventricular cyclic nucleotide content in the anaesthetized rat.
Carceles MD; Aleixandre F; Fuente T; López-Vidal J; Laorden ML
Eur J Anaesthesiol; 2003 Mar; 20(3):205-11. PubMed ID: 12650491
[TBL] [Abstract][Full Text] [Related]
12. Cyclic GMP protein kinase mediates negative metabolic and functional effects of cyclic GMP in control and hypertrophied rabbit cardiac myocytes.
Straznicka M; Gong G; Yan L; Scholz PM; Weiss HR
J Cardiovasc Pharmacol; 1999 Aug; 34(2):229-36. PubMed ID: 10445674
[TBL] [Abstract][Full Text] [Related]
13. Hemodynamic basis for the depressor activity of zaprinast, a selective cyclic GMP phosphodiesterase inhibitor.
Trapani AJ; Smits GJ; McGraw DE; McMahon EG; Blaine EH
J Pharmacol Exp Ther; 1991 Jul; 258(1):269-74. PubMed ID: 1649294
[TBL] [Abstract][Full Text] [Related]
14. Effects of topical methylene blue on cyclic GMP level, blood flow, and O2 consumption in focal cerebral ischaemia.
Wei HM; Tse J; Chi OZ; Weiss HR
Neurol Res; 1994 Dec; 16(6):449-55. PubMed ID: 7708136
[TBL] [Abstract][Full Text] [Related]
15. Effects of zaprinast on renal nerve stimulation-induced anti-natriuresis in anaesthetized dogs.
Sekizawa T; Shima Y; Yoshida K; Tanahashi M; Yoshida M; Suzuki-Kusaba M; Hisa H; Satoh S
Clin Exp Pharmacol Physiol; 1998 Dec; 25(12):1008-12. PubMed ID: 9887998
[TBL] [Abstract][Full Text] [Related]
16. Ageing blunts the effects of nitric oxide on myocardial O2 consumption.
Weiss HR; Lazar MJ; Tse J; Scholz PM
Clin Exp Pharmacol Physiol; 2002 Oct; 29(10):924-30. PubMed ID: 12207573
[TBL] [Abstract][Full Text] [Related]
17. Actions of 3-morpholinosydnonimin (SIN-1) on rabbit isolated penile erectile tissue.
Holmquist F; Fridstrand M; Hedlund H; Andersson KE
J Urol; 1993 Oct; 150(4):1310-5. PubMed ID: 8396690
[TBL] [Abstract][Full Text] [Related]
18. Relationship between cGMP and myocardial O2 consumption is altered in T4-induced cardiac hypertrophy.
Weiss HR; Rodriguez E; Tse J
Am J Physiol; 1995 Feb; 268(2 Pt 2):H686-91. PubMed ID: 7864195
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo interactions of nitrovasodilators and zaprinast, a cGMP-selective phosphodiesterase inhibitor.
Merkel LA; Rivera LM; Perrone MH; Lappe RW
Eur J Pharmacol; 1992 May; 216(1):29-35. PubMed ID: 1326438
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the ability of nicardipine, theophylline and zaprinast to restore cardiovascular haemodynamics following inhibition of nitric oxide synthesis.
Herity NA; Allen JD; Silke B; Adgey AA
Br J Pharmacol; 1994 Jun; 112(2):423-8. PubMed ID: 8075860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
